



February 06, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Press Release

Stock Code : BSE – 539787, NSE – HCG

This is to inform that the Board of Directors of the Company, at their meeting held on February 05, 2026, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, (“Financial Results”).

We enclose herewith the Press Release on the Financial Results of the Company.

Request you to take this on record.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

HealthCare Global Enterprises Limited

Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027

Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India

91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Q3 & 9M FY26 Financial & Business Update

Bangalore, 6th February 2026: Healthcare Global Enterprises Limited (HCG), India's largest dedicated cancer hospital network, under the brand "HCG", announced its financial results for the quarter and nine months ended 31st December 2025.

RESULTS HIGHLIGHTS (Consolidated)

Particulars (Rs. Mn.)	Q3FY26	Q3FY25	YoY	9MFY26	9MFY25	YoY
Revenue from Operations	6,331	5,586	13%	18,931	16,377	16%
Adjusted EBITDA ¹	1,108	923	20%	3,458	2,893	20%
Margin (%)	17.5%	16.5%	+98 bps	18.3%	17.7%	+60 bps
Adjusted PAT ² (Post IND AS)	6	70		216	371	

(1) Normalized for ESOP and one-time expenses, (2) Post Non controlling interest normalized for one-time exceptional item pertaining to the impact of the new Labour code

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said

"At HCG, our guiding principle is to deliver the right treatment, the first time, with a clear and consistent focus on patient outcomes. As a single-specialty oncology institution with a nationwide network, we have built a deeply integrated care model that brings together advanced diagnostics, genomics and multi-omics, organ-specific pathology, tumour-board-led decision-making, and emerging therapies such as CAR-T.

Our commitment to clinical research is reflected in the scale and quality of our published work, with HCG clinicians contributing to one of the largest bodies of oncology research from India and regularly representing the institution through podium presentations and poster sessions at leading international forums across the world.

This research-led approach, combined with the adoption of proven next-generation technologies, positions HCG at the forefront of cancer care. As we expand across India, we remain focused on translating innovation into measurable outcomes and extending high-quality oncology care to patients across both metro and non-metro markets."

Commenting on the results, Dr. Manish Mattoo, CEO HealthCare Global Enterprises Ltd. said,

"Our Q3 performance reflects steady execution across the network despite a seasonally softer quarter for the healthcare industry. We delivered revenues of ₹6,331 Mn with performance remaining balanced across our regional clusters, underscoring resilient demand for high-quality oncology care across key modalities including medical, radiation, and surgical oncology. The quarter further demonstrated the scalability of our model, with adjusted EBITDA increasing 20% year-on-year to ₹1,108 Mn and margins expanding by 98 basis points to 17.5%, underpinned by operating leverage.



HCG's focused single-specialty model, anchored in integrated care delivery, tumour-board-led clinical decision-making, and consistent clinical outcomes, continues to differentiate us in a competitive environment, supporting strong referral flows and patient trust. Alongside this, we have strengthened our leadership bandwidth to support the next phase of growth, with senior leadership augmentation now completed across marketing, domestic sales, and international business."

-End-

About Healthcare Global Enterprises Limited (HCG):

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is India's largest dedicated cancer hospital network. Through its network of 25 hospitals across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under "Milann", HCG operates fertility centers as well.

For updates and specific queries, please visit www.hcgel.com or feel free to contact

Healthcare Global Enterprises Limited

investors@hcgoncology.com

CDR India

Anoop Poojari / Suraj Digawalekar

Ph.: +91 98330 90434 / 98211 94418

Email: anoop@cdr-india.com / suraj@cdr-india.com

Safe Harbor

This document may contain forward-looking statements about Healthcare Global Enterprises Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.